Cascadian Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cascadian Therapeutics, Inc. - overview
Established
1958
Location
Seattle, WA-Washington, US
Primary Industry
Biotechnology
About
Oncothyreon is a biotechnology company dedicated to the development of oncology products.
Current Investors
BVF Partners, Ayer Capital Management, DAFNA Capital Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.oncothyreon.com
Total Amount Raised
Subscriber access only
Cascadian Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2007 | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 3,798,000 | 39,998,000 | 2,078,000 | 18,000 | 145,000 | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | 953.1% | (94.8%) | (99.1%) | 705.6% | (100.0%) | - | - | - | - | - |
| EBITDA (USD) | (20,089,000) | 7,554,000 | (16,750,000) | (19,022,000) | (24,093,000) | (27,901,000) | (40,083,000) | (49,790,000) | - | - | - |
| Operating Income (USD) | (20,335,000) | 7,132,000 | (17,019,000) | (19,484,000) | (24,699,000) | (28,499,000) | (41,223,000) | (50,835,000) | - | - | - |
| Operating Margin | (535.4%) | 17.8% | (819.0%) | (108244.4%) | (17033.8%) | - | - | - | - | - | - |
| % EBITDA Margin | (528.9%) | 18.9% | (806.1%) | (105677.8%) | (16615.9%) | - | - | - | - | - | - |
| NET Income (USD) | (20,340,000) | 7,125,000 | (17,219,000) | (15,618,000) | (42,656,000) | (3,415,000) | (38,759,000) | (49,963,000) | - | - | - |
| % Net Margin | (535.5%) | 17.8% | (828.6%) | (86766.7%) | (29417.9%) | - | - | - | - | - | - |
Cascadian Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | Cascadian Therapeutics, Inc. | - | ||||||||
| Add-on | Completed | Alpine Biosciences | - | ||||||||
| PIPE | Completed | Cascadian Therapeutics, Inc. | - | ||||||||
| Unspecified Round | Completed | Cascadian Therapeutics, Inc. | - | ||||||||
| Unspecified Round | Completed | Cascadian Therapeutics, Inc. | - |
Displaying 1 - 5 of 7
Cascadian Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.